StudyFinder
A seamless, Phase 1b/2 multiple ascending dose/proof of concept study of XTMAB-16 in patients with pulmonary sarcoidosis with or without extrapulmonary manifestations
Status: Recruiting
XTMAB-16 is a new, experimental drug and is part of a group of drugs known as tumor necrosis factor alpha (TNF α) inhibitors. TNF is a protein in your body that causes inflammation. TNF α inhibitors work by suppressing part of the immune response along with reducing inflammation. We are conducting this research study to see if XTMAB-16 will help in the treatment of pulmonary sarcoidosis.
Sex: Male or Female
Age Group: 18 years and over
Inclusion Criteria:
• Diagnosis of pulmonary sarcoidosis with some respiratory symptoms
• Must be taking 7.5 to 25 mg of prednisone daily and will to taper down dose
• Must be on an additional medication for the treatment of sarcoidosis
• Please contact umnsarc@umn.edu if you have any questions
Exclusion Criteria:
• Pregnancy or breast-feeding
Interventions:
Drug: XTMAB-16 or Placebo
Conditions:
Breathing, Lung & Sleep Health, Rare Diseases, Rare Diseases, Respiratory System
Keywords:
Clinics and Surgery Center (CSC), Sarcoidosis
Study Contact: Mandi DeGrote - carl1032@umn.edu
Principal Investigator: David Perlman
Phase: PHASE1
IRB Number: STUDY00020802
See this study on ClinicalTrials.gov